Open for inclusion

Phase I dose-escalating study to evaluate the safety and tolerability of LiPlaCis (Liposomal Cisplatin formulation) in patients with advanced or refractory tumours

Cancer type: Solide tumores

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, Liposomal cisplatin

Status: Open for inclusion

Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01861496?term=NCT01861496&rank=1